Industrial Manufacturing Process and Technical Specifications for 5-Azacytidine
- High-Purity Standards: Advanced crystallization techniques achieve >99.5% assay with minimal degradation impurities.
- Scalable Chemistry: Optimized coupling and deprotection steps ensure consistent batch-to-batch yield.
- Commercial Reliability: Secure bulk supply chains with full regulatory documentation and COA verification.
Chemical Profile and Pharmaceutical Application
5-Azacytidine, also known chemically as 4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one, is a critical nucleoside analog used extensively in the treatment of myelodysplastic syndromes (MDS). As a cytidine analog, it functions as a DNA hypomethylating agent, restoring normal function to dysplastic hematopoietic cells. In industrial contexts, this compound is sometimes referred to as Azacetidine. The molecule possesses a molecular weight of approximately 244.2 g/mol and exhibits specific solubility characteristics: it is soluble in dimethylsulfoxide (DMSO) but shows limited stability in aqueous environments over prolonged periods.
The commercial viability of this active pharmaceutical ingredient (API) depends heavily on controlling its degradation pathway. In aqueous solutions, the s-triazine ring is prone to hydrolytic degradation, yielding impurities such as N-(formylamidino)-N'-β-D-ribofuranosylurea (RGU-CHO) and 1-β-D-ribofuranosyl-3-guanylurea (RGU). Therefore, maintaining industrial purity requires strict control over solvent systems and processing temperatures to prevent hydrolysis during the work-up stages.
Optimizing the Manufacturing Process for Scale
The large-scale production of this nucleoside analog typically involves a multi-step organic synthesis. The process generally begins with the silylation of 5-azacytosine using reagents such as hexamethyldisilazane (HMDS) in the presence of ammonium sulfate. This step protects the reactive amine groups, facilitating the subsequent glycosylation reaction.
Following silylation, the protected base is coupled with a protected ribofuranose derivative, such as 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose. This coupling reaction often utilizes a Lewis acid catalyst. While non-metallic Lewis acids like trimethylsilyl trifluoromethanesulfonate are effective, metallic Lewis acids such as stannic chloride are frequently preferred for cost-efficiency in bulk manufacturing. However, the use of metallic reagents necessitates rigorous purification to remove residual metal ions to meet safety specifications.
When evaluating a specific synthesis route for commercial viability, manufacturers must prioritize methods that minimize water exposure during the quenching and isolation phases. The deprotection step typically involves reacting the protected intermediate with a base, such as sodium methoxide in methanol. Efficient removal of the solvent and acetyl protecting groups is critical to preventing the formation of degradation products before the final crystallization.
Purification Protocols and Impurity Control
Achieving pharmaceutical-grade quality requires sophisticated purification strategies beyond standard recrystallization. Data indicates that crude material often contains purity levels around 98.7%, with significant quantities of degradation impurities. To elevate this to API standards, advanced crystallization techniques are employed using solvents like N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), or DMSO.
Research into purification methods demonstrates that crystallization from DMF at controlled temperatures, followed by slurrying in acetone, significantly reduces residual solvent content and impurity profiles. For instance, cooling a DMF solution to -20°C rather than ambient temperature can reduce residual DMF levels from approximately 1780 ppm to 165 ppm. Furthermore, this method effectively lowers RGU-CHO impurities from 0.14% to below 0.02%.
The following table outlines the impact of different purification conditions on final product specifications:
| Purification Method | Final Purity (HPLC) | RGU-CHO Impurity | Residual DMF |
|---|---|---|---|
| Crystallization from DMSO/Toluene | 98.9% | 0.33% | High (23.13% total solvents) |
| Crystallization from DMF (Ambient) | 99.6% | 0.10% | 1780 ppm |
| Crystallization from DMF (-20°C) + Acetone Slurry | 99.95% | 0.01% | 165 ppm |
| Crystallization from DMA | 99.7% | 0.22% | 2000 ppm |
Adhering to ICH Q3C guidelines for residual solvents is mandatory. Class 2 solvents like DMF and DMA must be monitored and limited due to inherent toxicity, while Class 3 solvents like acetone are preferred for slurrying due to lower risk. The manufacturing process must include validated analytical methods, such as High-Pressure Liquid Chromatography (HPLC) coupled with mass spectrometry, to detect and quantify these trace impurities accurately.
Procurement Standards and Bulk Supply
For pharmaceutical companies and research institutions, securing a reliable supply chain is as critical as the chemical specifications themselves. Sourcing from a reputable global manufacturer ensures that the material meets consistent quality standards across multiple batches. Key procurement considerations include the availability of a comprehensive Certificate of Analysis (COA), which should detail assay purity, impurity profiles, residual solvent levels, and heavy metal content.
NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier partner for bulk procurement of high-quality pharmaceutical intermediates. By leveraging advanced process chemistry and strict quality control systems, NINGBO INNO PHARMCHEM CO.,LTD. delivers material suitable for large-scale production needs. Their commitment to technical excellence ensures that clients receive product with minimized degradation products and optimized physical properties for downstream formulation.
Stability data suggests that the solid-state material is stable under ambient temperatures and relative humidities up to 60% for extended periods. However, buyers should note that once reconstituted, the solution stability is time-sensitive. Therefore, procurement strategies should align with production schedules to minimize storage time of reconstituted solutions. Bulk pricing structures are often available for long-term contracts, providing cost certainty for commercial manufacturing campaigns.
Conclusion
The industrial production of 5-Azacytidine requires a delicate balance between chemical efficiency and purity control. By optimizing crystallization conditions and minimizing aqueous exposure during synthesis, manufacturers can achieve purity levels exceeding 99.5% with negligible degradation impurities. Partnering with an experienced supplier ensures access to material that meets these rigorous specifications, supporting the development of effective therapies for hematological disorders.